New Triple-Action drug takes on Hard-to-Treat cancers

NCT ID NCT07533708

Recruiting now Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug called HLX3902 in about 48 people with advanced prostate cancer or other solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. The drug is designed to help the immune system attack cancer cells more effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma gastric cancer metastatic prostate carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MCRPC OR ADVANCED/METASTATIC SOLID TUMORS

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, China
Guangxi Medical University Cancer Hospital
RECRUITING

Naning, China
Nanjing Drum Tower Hospital
RECRUITING

Nanjing, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, China
The First Affiliated Hospital of Xiamen University
RECRUITING

Xiamen, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.